XML 47 R21.htm IDEA: XBRL DOCUMENT v3.20.1
Segment Reporting
3 Months Ended
Mar. 31, 2020
Segment Reporting [Abstract]  
Segment Reporting
15.
Segment Reporting
 
 
 
 
 
 
The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. As a result, the financial information disclosed herein represents all of the material financial information related to the Company.
The following table represents the Company’s total revenue by geographic area (based on the location of the customer):
                 
 
Three Months Ended
 
 
March 31,
 
 
2020
 
 
2019
 
Revenue by customers’ geographic locations:
   
     
 
North America
   
48
%    
47
%
Europe
   
41
%    
40
%
APAC
   
11
%    
13
%
Other
   
0
%    
0
%
                 
Total revenue
   
100
%    
100
%
                 
 
 
 
 
 
 
Concentrations of Credit Risk and Significant Customers
Financial instruments that subject the Company to significant concentrations of credit risk primarily consist of cash and cash equivalents, marketable securities and accounts receivable. Per the Company’s investment policy, cash equivalents and marketable securities are invested in financial instruments with high credit ratings and credit exposure to any one issue, issuer (with the exception of U.S. treasury obligations) and type of instrument is limited. At March 31, 2020 and December 31, 2019, the Company had no investments associated with foreign exchange contracts, options contracts or other foreign hedging arrangements.
Concentration of credit risk with respect to accounts receivable is limited to customers to whom the Company makes significant sales. While a reserve for the potential
write-off
of accounts receivable is maintained, the Company has not written off any significant accounts to date. To control credit risk, the Company performs regular credit evaluations of its customers’ financial condition.
Revenue from significant customers that represent 10% or more of the Company’s total revenue is as follows:
                 
 
Three Months Ended
March 31,
 
 
2020
 
 
2019
 
MilliporeSigma
   
14
%    
16
%
GE Healthcare
   
N/A
     
13
%
 
 
 
 
 
 
There were no accounts receivable balances as of March 31, 2020 representing 10% or more of the Company’s total trade accounts receivable and royalties and other receivables balances. As of December 31, 2019, the accounts receivable balance with GE Healthcare represented 18% of the Company’s total trade accounts receivable and royalties and other receivables balances.